Pharvaris News

Pharvaris Analyst Ratings

BenzingaApr 22 13:27 ET

Pharvaris Analyst Ratings

BenzingaApr 15 12:44 ET

Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment

TipRanksApr 14 21:25 ET

Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials

TipRanksApr 12 01:39 ET

Pharvaris Analyst Ratings

BenzingaApr 11 09:57 ET

Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)

TipRanksApr 11 08:15 ET

Buy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial Stability

TipRanksApr 11 00:25 ET

Optimistic Buy Rating for Pharvaris on Advancement in Phase 3 HAE Treatment Trial

TipRanksMar 21 02:19 ET

Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target

BenzingaMar 19 09:07 ET

Pharvaris Analyst Ratings

BenzingaMar 19 09:05 ET

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)

TipRanksMar 19 08:50 ET

Pharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial Prospects

TipRanksMar 18 10:55 ET

Pharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE Treatment

TipRanksFeb 26 00:25 ET

Pharvaris Analyst Ratings

BenzingaFeb 14 13:22 ET

Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)

TipRanksFeb 14 08:15 ET

Buy Rating Affirmed for Pharvaris With Increased Price Target Following FDA Regulatory Advances

TipRanksJan 24 01:28 ET

Pharvaris Analyst Ratings

BenzingaJan 23 08:40 ET

Pharvaris Receives Sell Rating Amidst Competitive HAE Market and Phase 3 Uncertainties

TipRanksJan 23 07:25 ET

Strong Buy Rating Affirmed for Pharvaris With Enhanced Confidence in Deucrictibant's HAE Program

TipRanksJan 22 17:45 ET

Positive Clinical Trials and Strong Financial Position Support Buy Rating for Pharvaris

TipRanksJan 9 00:56 ET